![Mode of action of imatinib. The phosphorylation of a substrate is shown... | Download Scientific Diagram Mode of action of imatinib. The phosphorylation of a substrate is shown... | Download Scientific Diagram](https://www.researchgate.net/publication/7614675/figure/fig2/AS:280178145153026@1443811083296/Mode-of-action-of-imatinib-The-phosphorylation-of-a-substrate-is-shown-schematically.png)
Mode of action of imatinib. The phosphorylation of a substrate is shown... | Download Scientific Diagram
![Mode of action of imatinib. The phosphorylation of a substrate is shown... | Download Scientific Diagram Mode of action of imatinib. The phosphorylation of a substrate is shown... | Download Scientific Diagram](https://www.researchgate.net/profile/Tariq-Mughal/publication/7614675/figure/fig2/AS:280178145153026@1443811083296/Mode-of-action-of-imatinib-The-phosphorylation-of-a-substrate-is-shown-schematically_Q640.jpg)
Mode of action of imatinib. The phosphorylation of a substrate is shown... | Download Scientific Diagram
![Mode of action of imatinib on BCR-ABL. ADP, adenosine diphosphate; ATP,... | Download Scientific Diagram Mode of action of imatinib on BCR-ABL. ADP, adenosine diphosphate; ATP,... | Download Scientific Diagram](https://www.researchgate.net/publication/272414779/figure/fig1/AS:669031275192325@1536520894532/Mode-of-action-of-imatinib-on-BCR-ABL-ADP-adenosine-diphosphate-ATP-adenosine.png)
Mode of action of imatinib on BCR-ABL. ADP, adenosine diphosphate; ATP,... | Download Scientific Diagram
![Tyrosine Kinase Inhibitors in Leukemia and Cardiovascular Events | Arteriosclerosis, Thrombosis, and Vascular Biology Tyrosine Kinase Inhibitors in Leukemia and Cardiovascular Events | Arteriosclerosis, Thrombosis, and Vascular Biology](https://www.ahajournals.org/cms/asset/4a2f7ff7-f0e3-4cdf-99e1-1c4e90a83893/301ga1.jpg)
Tyrosine Kinase Inhibitors in Leukemia and Cardiovascular Events | Arteriosclerosis, Thrombosis, and Vascular Biology
![ON012380, a putative BCR-ABL kinase inhibitor with a unique mechanism of action in imatinib-resistant cells | Leukemia ON012380, a putative BCR-ABL kinase inhibitor with a unique mechanism of action in imatinib-resistant cells | Leukemia](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fleu.2009.300/MediaObjects/41375_2010_Article_BFleu2009300_Fig1_HTML.jpg)
ON012380, a putative BCR-ABL kinase inhibitor with a unique mechanism of action in imatinib-resistant cells | Leukemia
![Overexpression of Tpl2 is linked to imatinib resistance and activation of MEK‐ERK and NF‐κB pathways in a model of chronic myeloid leukemia - Chorzalska - 2018 - Molecular Oncology - Wiley Online Library Overexpression of Tpl2 is linked to imatinib resistance and activation of MEK‐ERK and NF‐κB pathways in a model of chronic myeloid leukemia - Chorzalska - 2018 - Molecular Oncology - Wiley Online Library](https://febs.onlinelibrary.wiley.com/cms/asset/2324b573-8610-4847-afbd-d9844bcf789e/mol212186-toc-0001-m.jpg?trick=1672056187956)
Overexpression of Tpl2 is linked to imatinib resistance and activation of MEK‐ERK and NF‐κB pathways in a model of chronic myeloid leukemia - Chorzalska - 2018 - Molecular Oncology - Wiley Online Library
![Gold Nanoparticles for BCR-ABL1 Gene Silencing: Improving Tyrosine Kinase Inhibitor Efficacy in Chronic Myeloid Leukemia - ScienceDirect Gold Nanoparticles for BCR-ABL1 Gene Silencing: Improving Tyrosine Kinase Inhibitor Efficacy in Chronic Myeloid Leukemia - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2162253117301737-fx1.jpg)